© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
June 10, 2019
The results of the phase II trial examining combination immunotherapy were presented during the ASCO 2019 meeting.
Findings from a pooled analysis of two phase III trials, COMBI-d and COMBI-v, centered on outcomes with first-line dabrafenib plus trametinib vs either agent alone.
June 07, 2019
Data from the largest randomized neoadjuvant trial in resectable stage IIIB–IVM1a melanoma to date were presented at ASCO 2019.
The investigators looked at whether whole-brain radiotherapy improved outcomes in patients with melanoma brain metastasis.